HC Wainwright Brokers Boost Earnings Estimates for ORKA

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Research analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for shares of Oruka Therapeutics in a note issued to investors on Tuesday, May 27th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.47) per share for the quarter, up from their previous forecast of ($0.49). HC Wainwright has a "Buy" rating and a $45.00 price objective on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Oruka Therapeutics' Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.11) EPS, Q1 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.71) EPS and FY2026 earnings at ($2.76) EPS.

Other equities analysts have also issued research reports about the company. Wolfe Research initiated coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $20.00 target price on the stock. BTIG Research initiated coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They set a "buy" rating on the stock. Wedbush reissued an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 15th. Finally, Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $40.38.

Oruka Therapeutics Trading Down 6.8%

ORKA traded down $0.81 during mid-day trading on Thursday, hitting $11.04. 327,851 shares of the stock were exchanged, compared to its average volume of 225,192. The firm's fifty day moving average is $9.73 and its two-hundred day moving average is $13.77. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $31.13. The company has a market cap of $413.35 million, a PE ratio of -1.76 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after acquiring an additional 1,572,853 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Oruka Therapeutics by 2,348.6% in the 4th quarter. Geode Capital Management LLC now owns 342,418 shares of the company's stock valued at $6,643,000 after acquiring an additional 328,434 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in Oruka Therapeutics during the 4th quarter worth approximately $54,000. Wellington Management Group LLP grew its stake in Oruka Therapeutics by 15.8% during the 4th quarter. Wellington Management Group LLP now owns 95,089 shares of the company's stock worth $1,844,000 after buying an additional 12,952 shares during the last quarter. Finally, Barclays PLC purchased a new position in Oruka Therapeutics during the 4th quarter worth approximately $1,446,000. Hedge funds and other institutional investors own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.